Argene

Parc Technologique Delta Sud
09120 Varilmes
France

Phone: +33 5 616961-00
Fax: +33 5 616961-01
http://www.argene.com
infotech@argene.com

Manufacturers

Company Figures
Number of employees 20-49
Sales volume 1-9 Mio US $
Export content max. 50%
Year of foundation 1994
Area of business Diagnostics

Company Profile

About Argene Biosoft

THE IN VITRO DIAGNOSTIC INDUSTRY
As a key partner of public and private medical biological analysis laboratories, the in vitro diagnostics industry provides the reagents and materials required for the analysis of blood, urine, cerebrospinal fluid or any other biological sample.

ARGENE specialises in this domain and offers products and reagents for the detection of infectious agents in laboratories. These tests may be carried out for diagnostic or preventive purposes, but also as part of the follow-up of certain treatments.

OUR KNOW-HOW
With over twenty years of experience, ARGENE S.A. has a strong presence in the domain of diagnostic virology.
Ever attentive to the desires, needs and imperatives of microbiology, we are proud to contribute to decisive scientific progress in the area of direct diagnosis of infectious agents (rapidity, specificity, sensitivity).

Created at a time when monoclonal antibody applications were in their infancy, ARGENE has developed products that are today considered to be the reference products in their domain (CINAkit for HCMV antigenaemia tests, monoclonal antibodies and complete kits for the identification of respiratory viruses, antibodies against HSV 1/2, VZV, rotavirus, EBV, HAV, toxoplasma, etc…).

We anticipated the importance that molecular biology was going to assume, particularly in terms of gene amplification techniques for the detection and early identification of viruses. We also provide a large range of kits for the detection and amplification of viral genomes, for herpes virus, enterovirus, adenovirus, papillomavirus, calici/astrovirus, etc…

ARGENE is also active in distribution, offering its clients not only its own products, but also a complementary range of products manufactured by other companies. We therefore also supply products such as rapid detection kits for influenza or streptococcus A (QUIDEL) to French laboratories.

Many other in vitro diagnostics companies use raw materials originating directly from our own research and production. These products, known as OEM (Original Equipment Manufacture), are essential components of the products of the leaders in this field.

FROM YESTERDAY TO TODAY
In 1994, Ab-SERVICES SARL bought the BIOSOFT department and its clone bank, together with the assets, know-how, marks and patents of CLONATEC. The management and employees founded ARGENE SA to exploit this acquisition.

Located at the foot of the Pyrenees, we develop new technologies in the framework of a clear policy of quality, both from a technical and norms point of views and with respect to “quality-of-life”.

At the end of 1996, ARGENE positioned itself and began to distribute its products on the American market via a subsidiary of Ab-SERVICES, ARGENE Inc. In 1998, CINAkit CMV received official FDA 510k licensing.

In August 1999, we moved into new laboratories, designed for the development of commercial activity, research and production according to good manufacturing practice (GMP) norms.

In 2002, ARGENE signed a distribution agreement with Quality Control for Molecular Diagnostics (QCMD). This organisation, supported and recognised by the European Society for Clinical Virology (ESCV) and the European Society for Clinical Microbiology and Infectious Disease (ESCMID), provides us with quality control, which we distribute worldwide.

On May 26th 2003, G-MED certifies that the quality assurance system developed by Argene S.A. for the activities; manufacturing, design and sales for in vitro diagnostic reagents of the field of infectiology, complies with the requirements of the international standards: ISO 9001 (2000) and ISO 13485 (2001). Our products for diagnostic use are entitled to carry the CE label.

ARGENE also collaborates closely with the academic sector. Most of our products owe their existence, to some extent, to this approach.